Qurient Co. Ltd (115180) - Total Assets
Based on the latest financial reports, Qurient Co. Ltd (115180) holds total assets worth ₩54.70 Billion KRW (≈ $37.07 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Qurient Co. Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Qurient Co. Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Qurient Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Qurient Co. Ltd net assets for net asset value and shareholders' equity analysis.
Qurient Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Qurient Co. Ltd's total assets of ₩54.70 Billion consist of 83.2% current assets and 16.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 33.9% |
| Accounts Receivable | ₩536.84 Million | 0.9% |
| Inventory | ₩46.26 Million | 0.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩4.72 Billion | 7.6% |
| Goodwill | ₩666.75 Million | 1.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how Qurient Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 115180 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qurient Co. Ltd's current assets represent 83.2% of total assets in 2025, a decrease from 95.3% in 2014.
- Cash Position: Cash and equivalents constituted 33.9% of total assets in 2025, down from 94.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 7.6% of total assets.
Qurient Co. Ltd Competitors by Total Assets
Key competitors of Qurient Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Qurient Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.26 | 10.98 | 14.87 |
| Quick Ratio | 19.24 | 10.95 | 14.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩42.24 Billion | ₩39.85 Billion | ₩50.09 Billion |
Qurient Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Qurient Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.67 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.5% |
| Total Assets | ₩61.99 Billion |
| Market Capitalization | $434.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Qurient Co. Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Qurient Co. Ltd's assets decreased by 5.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Qurient Co. Ltd (2014–2025)
The table below shows the annual total assets of Qurient Co. Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩61.99 Billion ≈ $42.01 Million |
-5.46% |
| 2024-12-31 | ₩65.57 Billion ≈ $44.44 Million |
+24.89% |
| 2023-12-31 | ₩52.50 Billion ≈ $35.58 Million |
+36.69% |
| 2022-12-31 | ₩38.41 Billion ≈ $26.03 Million |
-33.34% |
| 2021-12-31 | ₩57.62 Billion ≈ $39.05 Million |
-5.24% |
| 2020-12-31 | ₩60.81 Billion ≈ $41.21 Million |
+196.44% |
| 2019-12-31 | ₩20.51 Billion ≈ $13.90 Million |
-52.51% |
| 2018-12-31 | ₩43.20 Billion ≈ $29.27 Million |
+175.52% |
| 2017-12-31 | ₩15.68 Billion ≈ $10.62 Million |
-40.25% |
| 2016-12-31 | ₩26.24 Billion ≈ $17.78 Million |
+580.17% |
| 2015-12-31 | ₩3.86 Billion ≈ $2.61 Million |
-66.25% |
| 2014-12-31 | ₩11.43 Billion ≈ $7.75 Million |
-- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more